Gastrointestinal Involvement in Extra-Digestive Disease: Which Is the Role of Fecal Calprotectin?

Saviano, Angela; Candelli, Marcello; Zanza, Christian; Piccioni, Andrea; Migneco, Alessio; Ojetti, Veronica

doi:10.3390/medicina58101384

Cited by 3 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It's important to note that elevated fecal calprotectin levels are not specific to COVID-19 and can be influenced by various factors such as other infections, inflammatory conditions, or dietary factors[ 117 , 118 ]. In addition, some COVID-19-associated gastrointestinal manifestations are due to autonomic changes and not inflammation, in which fecal calprotectin could be normal despite gastrointestinal symptoms[ 119 ].…”

Section: Discussionmentioning

confidence: 99%

Fecal calprotectin in pediatric gastrointestinal diseases: Pros and cons

Al-Beltagi,

Saeed,

Bediwy

et al. 2024

World J Clin Pediatr

View full text Add to dashboard Cite

BACKGROUND Fecal calprotectin is a valuable biomarker for assessing intestinal inflammation in pediatric gastrointestinal diseases. However, its role, pros, and cons in various conditions must be comprehensively elucidated. AIM To explore the role of fecal calprotectin in pediatric gastrointestinal diseases, including its advantages and limitations. METHODS A comprehensive search was conducted on PubMed, PubMed Central, Google Scholar, and other scientific research engines until February 24, 2024. The review included 88 research articles, 56 review articles, six meta-analyses, two systematic reviews, two consensus papers, and two letters to the editors. RESULTS Fecal calprotectin is a non-invasive marker for detecting intestinal inflammation and monitoring disease activity in pediatric conditions such as functional gastrointestinal disorders, inflammatory bowel disease, coeliac disease, coronavirus disease 2019-induced gastrointestinal disorders, gastroenteritis, and cystic fibrosis-associated intestinal pathology. However, its lack of specificity and susceptibility to various confounding factors pose challenges in interpretation. Despite these limitations, fecal calprotectin offers significant advantages in diagnosing, monitoring, and managing pediatric gastrointestinal diseases. CONCLUSION Fecal calprotectin holds promise as a valuable tool in pediatric gastroenterology, offering insights into disease activity, treatment response, and prognosis. Standardized protocols and guidelines are needed to optimize its clinical utility and mitigate interpretation challenges. Further research is warranted to address the identified limitations and enhance our understanding of fecal calprotectin in pediatric gastrointestinal diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Fecal calprotectin in pediatric gastrointestinal diseases: Pros and cons

Al-Beltagi,

Saeed,

Bediwy

et al. 2024

World J Clin Pediatr

View full text Add to dashboard Cite

show abstract

“…It is more abundant in the stool than other body fluids. It increases in many intestinal pathologies such as inflammatory bowel disease, non-steroidal antiinflammatory drugs (NSAID) regular use, and even colorectal cancers (12) .…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Faecal Calprotectin Level in Psoriatic and Hidradenitis Suppurativa Patients as a Model of an Autoimmune and Auto-Inflammatory Disease Retrospectively

2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Psoriasis represents an example of an autoimmune disease where adaptive immune system activation, T helper 17 secretory cytokines secretion such as IL 17 and IL 21, and self-antigen intolerance are the hallmarks of its pathology. Hidradenitis suppurativa on the contrary, could be described as a neutrophilic dermatosis disease while recurrent abscess formation and skin fibrosis compose the clinical features. Inflammatory bowel diseases association with diverse dermatological diseases is well known. Objectives: To evaluate the role of the diagnostic application of fecal calprotectin (FCP) in patients with either hidradenitis suppurativa or psoriasis. Patients and Methods: A lanoitces-nstll study was done on 20 patients with varying severity of plaque psoriasis and 10 patients with hidradenitis suppurativa (HS). Demographic data, duration of illness, area extent affected, gastrointestinal symptoms, and severity scores were taken such as Psoriasis Assessment and Severity Index (PASI) score and Hurley staging for psoriasis and HS retrospectively. A fecal calprotectin (FCP) assay was also tested. Results: While the psoriasis group demonstrated significantly higher age (median = 51 vs. 25 years, P < 0.001) than the HS group, hidradenitis suppurativa showed significantly higher FCP levels (median = 215 vs. 83, respectively, P = 0.013). Significant strong positive correlations between FCP and severity were observed in the hidradenitis suppurativa group (r = 0.921, P < 0.001). Conclusion:To our knowledge, our study could be the first comparative study between hidradenitis suppurativa and psoriasis in relation to fecal calprotectin.

show abstract